Skip to main content
Premium Trial:

Request an Annual Quote

Need Cash? Tullis-Dickerson Closes $122M Healthcare Fund for Seed- and Mid-Stage Firms

NEW YORK, Oct. 30 - Seed- or mid-stage biotech shops hard-up for cash may consider looking to Tullis-Dickerson, which recently said it closed a $122 million private-equity fund.

 

Cash from this fund, the company's fourth-largest to date, will be divided between genomic-tool vendors, informatics companies, drug discoverers, and medical-device makers, according to a spokeswoman.

 

Specifically, Tullis-Dickerson said it plans to spend between $5 million and $10 million on roughly 15 companies based in the United States. The fund, called Tullis-Dickerson Capital Focus III, has already invested in four firms, each of them a drug discoverer.

 

Click here for more information.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.